Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.21M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.39 | 52 Weeks Range 0.20 - 3.97 | Updated Date 07/9/2025 |
52 Weeks Range 0.20 - 3.97 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -178.9% | Return on Equity (TTM) -473.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4743825 | Price to Sales(TTM) - |
Enterprise Value 4743825 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 29008000 | Shares Floating 24099953 |
Shares Outstanding 29008000 | Shares Floating 24099953 | ||
Percent Insiders 0.25 | Percent Institutions 1.03 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex, Inc. is a clinical-stage gene therapy company focused on developing new therapies for large patient populations with cancer and diabetes. Founded in 2009, it has focused on gene therapy technologies and progressed through clinical trials.
Core Business Areas
- Oncology: Genprex focuses on developing gene therapies for cancer, particularly small cell lung cancer (SCLC) and other solid tumors. Their lead product candidate is REQORSAu2122 (quaratusugene ozeplasmid) for SCLC.
- Diabetes: Genprex is also developing gene therapies for diabetes. Their pipeline includes therapies designed to modulate blood glucose levels.
Leadership and Structure
Genprex is led by a team with experience in biotechnology and pharmaceutical development. Its organizational structure consists of research and development, clinical operations, and administrative functions. Rodney Varner is the CEO.
Top Products and Market Share
Key Offerings
- REQORSAu2122 (quaratusugene ozeplasmid): REQORSA is Genprex's lead drug candidate, a gene therapy for small cell lung cancer (SCLC). It is currently in clinical trials. Market share data is not yet available as the product is not yet commercialized. Competitors include companies developing traditional chemotherapy regimens and novel immunotherapies for SCLC, such as Bristol Myers Squibb (BMY) with Opdivo, and AstraZeneca (AZN) with Imfinzi.
- GPX-002: GPX-002 is a preclinical stage therapy for Type 1 diabetes. Competitors include companies developing diabetes therapies such as Vertex Pharmaceuticals (VRTX) and Provention Bio (acquired by Sanofi (SNY)).
Market Dynamics
Industry Overview
The gene therapy market is growing rapidly, driven by advances in biotechnology and the potential to treat previously incurable diseases. It is a competitive space with many companies vying to be the first to market with innovative gene therapies.
Positioning
Genprex is positioning itself as a leader in gene therapy for cancer and diabetes, focusing on areas with high unmet medical need. Their competitive advantage lies in their gene therapy platform and clinical trial progress.
Total Addressable Market (TAM)
The global gene therapy market is projected to reach billions of dollars in the coming years. Genprex is targeting specific segments within this market, such as SCLC and diabetes, each representing a significant TAM. Their positioning depends on the success of their clinical trials and commercialization strategy.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Focus on unmet medical needs
- Clinical-stage product candidates
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into other disease areas
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- AZN
- BMY
- VRTX
- SNY
Competitive Landscape
Genprex faces competition from established pharmaceutical companies with greater resources. Its advantage lies in its unique gene therapy platform and focus on specific indications. However, their lack of established market presence and marketed products puts them at a disadvantage until they achieve regulatory approval and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by progress in clinical trials and securing funding.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of their therapies. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing REQORSA through clinical trials, exploring partnerships, and expanding the pipeline.
Summary
Genprex is a clinical-stage gene therapy company with potential in oncology and diabetes, particularly with REQORSA for SCLC. Its success hinges on positive clinical trial outcomes and securing partnerships. The company faces financial constraints and competition from larger pharmaceutical companies. Genprex needs to successfully navigate the regulatory landscape and demonstrate clinical efficacy to realize its potential. Their proprietary gene therapy platform represents significant promise.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
- Market Research Reports (where available)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies is inherently risky, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.genprex.com |
Full time employees 15 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company's lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials for the treatment of non-small cell lung cancer and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreas; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.